Patents by Inventor Ulrich Graedler

Ulrich Graedler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220144828
    Abstract: Atropisomers, solid forms, salt forms, and deuterated derivatives of the ATM inhibitor 8-(1,3-Dimethyl-1H-pyrazol-4-yl)-1-(3-fluoro-5-methoxypyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydroimidazo[4,5-c]quinolin-2-one as well as compositions thereof are provided.
    Type: Application
    Filed: March 25, 2020
    Publication date: May 12, 2022
    Applicant: Merck Patent GmbH
    Inventors: Thomas Fuchss, Axel Becker, Holger Kubas, Ulrich Graedler
  • Publication number: 20180230162
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
    Type: Application
    Filed: April 16, 2018
    Publication date: August 16, 2018
    Inventors: Catherine JORAND-LEBRUN, Theresa L. JOHNSON, Ulrich GRAEDLER, Xuliang JIANG, Santosh KULKARNI
  • Patent number: 9975902
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: May 22, 2018
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Theresa L. Johnson, Ulrich Graedler, Xuliang Jiang, Santosh Kulkarni
  • Publication number: 20170283427
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
    Type: Application
    Filed: March 30, 2017
    Publication date: October 5, 2017
    Inventors: Catherine JORAND-LEBRUN, Theresa L. JOHNSON, Ulrich GRAEDLER, Xuliang JIANG, Santosh KULKARNI
  • Publication number: 20170283425
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
    Type: Application
    Filed: March 30, 2017
    Publication date: October 5, 2017
    Inventors: Catherine JORAND-LEBRUN, Theresa L. JOHNSON, Ulrich GRAEDLER, Xuliang JIANG, Didier ROCHE, Hugues LEMOINE, Marine GILARDONE
  • Publication number: 20170283426
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
    Type: Application
    Filed: March 30, 2017
    Publication date: October 5, 2017
    Inventors: Catherine JORAND-LEBRUN, Theresa L. JOHNSON, Ulrich GRAEDLER, Xuliang JIANG, Didier ROCHE, Hugues LEMOINE, Marine GILARDONE
  • Patent number: 8841459
    Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: September 23, 2014
    Assignee: Merck Serono SA
    Inventors: Holger Deppe, Matthias Schwarz, Ulrich Abel, Achim Feurer, Ulrich Grädler, Kerstin Otte, Renate Sekul, Meinolf Thiemann, Andreas Goutopoulos, Xuliang Jiang
  • Publication number: 20140051686
    Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: July 11, 2013
    Publication date: February 20, 2014
    Inventors: Ulrich Abel, Holger Deppe, Achim Feurer, Ulrich Grädler, Kerstin Otte, Renate Sekul, Meinolf Thiemann, Andreas Goutopoulos, Matthias Schwarz, Xuliang Jiang
  • Patent number: 8648201
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R7 and Y have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumors and for the treatment of inflammatory diseases.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: February 11, 2014
    Assignee: MERCK PATENT GmbH
    Inventors: Michel Calderini, Margarita Wucherer-Plietker, Ulrich Graedler, Christina Esdar
  • Patent number: 8524911
    Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: September 3, 2013
    Assignee: Merck Serono SA
    Inventors: Ulrich Abel, Holger Deppe, Achim Feurer, Ulrich Grädler, Kerstin Otte, Renate Sekul, Meinolf Thiemann, Andreas Goutopoulos, Matthias Schwarz, Xuliang Jiang
  • Patent number: 8492440
    Abstract: Novel difluorophenyldiacylhydrazide derivatives of the formula I, in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in claim 1, are kinase inhibitors and can be used for the treatment of diseases and complaints such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in any type of fibroses, inflammatory processes, tumours and tumour diseases.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: July 23, 2013
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Ulrich Graedler, Norbert Beier, Rolf Gericke, Florian Lang
  • Patent number: 8420820
    Abstract: Compounds of the formula I in which X, R1, R2, R3, R4 and R6 have the meanings indicated in claim 1, are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: April 16, 2013
    Assignee: Merck Patent GmbH
    Inventors: Margarita Wucherer-Plietker, David Bruge, Dirk Finsinger, Ulrich Graedler, Dieter Dorsch, Christina Esdar
  • Publication number: 20120295889
    Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: May 16, 2012
    Publication date: November 22, 2012
    Applicant: Merck Serono S.A.
    Inventors: Ulrich Abel, Holger Deppe, Achim Feurer, Ulrich Grädler, Kerstin Otte, Renate Sekul, Meinolf Thiemann, Andreas Goutopoulos, Matthias Schwarz, Xuliang Jiang
  • Patent number: 8202882
    Abstract: Novel 5-cyanothienopyridines of the formula (I), in which R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of TGF-beta receptor kinase, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: June 19, 2012
    Assignee: Merck Patent Gesellschaft MIT Beschränkter Haftung
    Inventors: Guenter Hoelzemann, Ulrich Graedler, Hartmut Greiner, Christiane Amendt, Djordje Musil, Per Hillertz
  • Patent number: 8198457
    Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: June 12, 2012
    Assignee: Merck Serono S.A.
    Inventors: Ulrich Abel, Holger Deppe, Achim Feurer, Ulrich Grädler, Kerstin Otte, Renate Sekul, Meinolf Thiemann, Andreas Goutopoulos, Matthias Schwarz, Xuliang Jiang
  • Publication number: 20120115861
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R7 and Y have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumours and for the treatment of inflammatory diseases.
    Type: Application
    Filed: June 17, 2010
    Publication date: May 10, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Michel Calderini, Margarita Wucherer-Plietker, Ulrich Graedler, Christina Esdar
  • Patent number: 8093240
    Abstract: Novel triazole derivatives are inhibitors of TGF-beta receptor I kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: November 24, 2006
    Date of Patent: January 10, 2012
    Assignee: Merck Patent GmbH
    Inventors: Bertram Cezanne, Christiane Amendt, Hartmut Greiner, Ulrich Graedler, Guenter Hoelzemann
  • Publication number: 20110224192
    Abstract: The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: May 20, 2011
    Publication date: September 15, 2011
    Inventors: Ulrich Abel, Holger Deppe, Achim Feurer, Ulrich Grädler, Kerstin Otte, Renate Sekul, Meinolf Thiemann, Andreas Goutopoulos, Matthias Schwarz, Xuliang Jiang
  • Publication number: 20110224302
    Abstract: Novel difluorophenyldiacylhydrazide derivatives of the formula I, in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in claim 1, are kinase inhibitors and can be used for the treatment of diseases and complaints such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in any type of fibroses, inflammatory processes, tumours and tumour diseases
    Type: Application
    Filed: November 2, 2009
    Publication date: September 15, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Thomas Fuchss, Ulrich Graedler, Norbert Beier, Rolf Gericke, Florian Lang
  • Publication number: 20110218198
    Abstract: Compounds of the formula I in which X, R1, R2, R3, R4 and R6 have the meanings indicated in Claim 1, are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.
    Type: Application
    Filed: June 4, 2009
    Publication date: September 8, 2011
    Applicant: MERCK PATENT GESELLSCHAFT
    Inventors: Margarita Wucherer-Plietker, David Bruce, Dirk Finsinger, Ulrich Graedler, Dieter Dorsch, Christina Esdar